Document is current
Any future updates will be listed below
-
Authors
Hafner, Michael https://orcid.org/0009-0008-9025-259X
Asani, Ben
Eckardt, Franziska
Siedlecki, Jakob
Schworm, Benedikt
Priglinger, Siegfried G.
Schiefelbein, Johannes
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (031L0210A)
Helmholtz Association (ZT-I-PF-5-01)
- License Information
-
More Information
Article History
Received: 25 January 2025
Accepted: 4 March 2025
First Online: 25 March 2025
Declarations
:
: Ben Asani has received speaker honoraria and research support from Novartis and research support from Alcon. Franziska Eckardt has received speaker honoraria from Novartis. Jakob Siedlecki has received honoraria and served on advisory boards for Novartis, AbbVie/Pharm-Allergan, Bayer, Roche, Apellis and Hexal. Additionally, he has received honoraria from Heidelberg Engineering. Benedikt Schworm has received speaker honoraria from Novartis. Siegfried G. Priglinger has received advisory board honoraria from Novartis, Pharm-Allergan, Bayer, and Alcon. He has also received consulting or advisory board honoraria from Zeiss, BVI, Roche and Bausch & Lomb. Johannes Schiefelbein has received speaker honoraria and research support from Novartis. Michael Hafner declares no financial disclosures. All authors affirm that these conflicts of interest do not affect or influence the design, conduct, or reporting of this study.
: Ethics approval was granted by the Institutional Review Board of the Faculty of Medicine, LMU Munich, study ID: 20-0382, and the study followed the principles of the Declaration of Helsinki of 1964 and its later amendments. Data extraction was carried out completely anonymously, with no reference to patient names or IDs. Informed consent was obtained in accordance with institutional guidelines. All patients had previously provided consent for the use of their anonymized medical data for research purposes at the time of their initial treatment or follow-up visits.
